The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000762358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
4/05/2026
Date registered
Help: Date registered
26/06/2026
Date last updated
Help: Date last updated
26/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
26/06/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of GV-100 (Part 1 & Part 2)
Scientific title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single
and Multiple Ascending Doses (Part 1 & Part2) of GV-100 with Food-Effect and Drug-Drug
Interaction Evaluations in Healthy Participants
Additional trial identifiers [1] 316873 0
GV-GV100-CT01
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Autosomal Dominant Polycystic Kidney Disease (ADPKD) 341270 0
Condition category
Condition code
Renal and Urogenital 337346 337346 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug–drug interaction (DDI) potential of GV-100 following oral administration in healthy participants. The study is divided into four parts: Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Food Effect (FE), and Drug–Drug Interaction (DDI).
Subjects will be confined on site and observed during dosing, and IP usage will be documented.

Part 1: Single Ascending Dose (SAD)

The SAD part will assess the safety, tolerability, and PK of single oral doses of GV-100 at 150 mg, 400 mg, 800 mg, and 1200 mg. Approximately 32 participants will be enrolled across 4 cohorts, with 8 participants per cohort randomized in a 3:1 ratio (6 receiving GV-100 and 2 receiving placebo).
Participants will be screened between Day -28 and Day -2, admitted on Day -1, and confined through completion of assessments on Day 2, with a follow-up visit on Day 8 (±1 day). Each cohort will use a staggered dosing strategy, with 2 sentinel participants (1 active, 1 placebo) dosed first, followed by the remaining participants at least 24 hours later, subject to review of safety data and approval by the Principal Investigator or delegate.

Part 2: Multiple Ascending Dose (MAD)

The MAD part will be initiated after the Safety Review Committee (SRC) reviews and approves safety, tolerability, and PK data from a SAD dose level higher than the planned MAD starting dose. GV-100 will be administered orally at 400 mg, 800 mg, and 1200 mg.

Approximately 24 participants will be enrolled across 3 cohorts, with 8 participants per cohort randomized in a 3:1 ratio (6 receiving GV-100 and 2 receiving placebo). Participants will be screened between Day -28 and Day -2, admitted on Day -1, and confined through completion of assessments on Day 15, followed by a Day 21 (±1 day) follow-up.

The SRC will review safety, tolerability, and PK data for each dose level and decide on dose escalation, de-escalation, repetition, or termination. Dose escalation will be guided by PK exposure limits, ensuring predicted exposures do not exceed a Cmax of 24,500 ng/mL or an AUC0–24 of 161,000 hr·ng/mL, corresponding to the NOAEL identified in female dogs.

Intervention code [1] 333605 0
Treatment: Drugs
Description of the comparator or control
Matching-placebo oral suspension, compounded at the clinical site pharmacy from 1,200 mg of microcrystalline cellulose with the dosing vehicle [0.1% polysorbate 80, 0.05% sucralose, 0.1% sodium benzoate, 0.3% sodium alginate, and purified water
Control group
Placebo

Outcomes
Primary outcome [1] 344904 0
Safety & Tolerability. This will be assessed as a composite outcome.
Timepoint [1] 344904 0
Part 1: Single Ascending Dose (SAD) Vital Signs: At screening, on Day -1, on Day 1 prior to dosing, and at follow-up on Day 8 post dose (or ET (as soon as possible)). Safety laboratory tests: At screening, on Day -1, at 24 hours post-dose (Day 2), and at follow-up Day 8 post dose (or ET(as soon as possible)). 12Lead ECG: At screening, on Day -1, on Day 1 prior to dosing and at 4, 12, and 24 (Day 2) hours post-dose, and at follow-up Day 8 (or ET). Adverse Event: From screening to FU (Day 8 post dose) /EOS (Day8 post dose) /ET (as soon as possible) Part 2: Multiple Ascending Dose (MAD) Vital Signs: At screening, on Day -1, on Days1, 5, 8, and 11 prior to dosing, on Day 15 prior to discharge, and at follow-up (Day21) (or ET (as soon as possible)). Safety laboratory tests: At screening, on Day -1, on Days 2, 5, 8, and 11 prior to dosing, on Day 15 prior to discharge, and at follow-up (Day21) (or ET (as soon as possible)). 12Lead ECG: At screening, on Day -1, on Day 1 prior to dosing and at 4, 12, and 24 (prior to dosing on Day 2) hours post-dose, on Days 5,8, and 11 prior to dosing, on Day 14 prior to dosing and at 4, 12, and 24(Day 15) hours post-dose, and at (Day21) (or ET(as soon as possible)). Adverse Event: From screening to FU(Day21) /EOS(Day21) /ET(as soon as possible).
Secondary outcome [1] 459881 0
Urine PK parameters of GV-100 including but not limited to total amount of unchanged GV-100 excreted in the urine (Ae), fraction of unchanged GV-100 excreted in the urine (fe), and renal clearance (CLr).
Timepoint [1] 459881 0
Part 1; SAD Day 1: Pre-dose, 0.5hours ,1 hours, 2 hours, 4 hours, 6 hours, 8 hours & 12 hours Day 2: 24hours Part 2: MAD Day 1: Pre-dose, 0.5 hours, 1 hours, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours Day2: 24 hours( 30mins prior dosing) Day 3 to 13 - Pre dose (30 min prior to dosing) Day 14: pre-dose(within 30minutes prior dosing), 0.5 hours, 1 hours, 2 hours, 4 hours, 6 hours, 8 hours & 12 hours Day 15: 24 hours
Secondary outcome [2] 459882 0
Part 1 SAD and Part 2 MAD Only • Urine PK parameters of GV-100 including, but not limited to: total amount of unchanged GV-100 excreted in the urine (Ae), fraction of unchanged GV-100 excreted in the urine (fe), and renal clearance (CLr).
Timepoint [2] 459882 0
Part 1: pre-dose and 0-6, 6-12, 12-18, and 18-24 hours post-dose. Part 2: on Days 1 and 14 at pre-dose and 0-6, 6-12, 12-18, and 18-24 hours post-dose

Eligibility
Key inclusion criteria
- Male or female participants, aged more than or equal 18 to less than or equal to 65 years at the time of providing informed consent, who are non-smokers (no use of tobacco or nicotine-containing products within 3 months prior to screening), with a body mass index (BMI) greater than 18.0 and less than 32.0 kilogram/meter square, and a minimum body weight of 50.0 kilogram.

- Healthy individuals, as determined by the Principal Investigator or delegate, defined as:
a. No clinically significant illness or surgical procedures within 4 weeks prior to study drug administration.
b. No clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, or metabolic disorders.

- Capable of understanding the study procedures and willing to provide written informed consent prior to participation.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
- Any clinically significant abnormal finding on physical examination, as determined by the Principal Investigator or delegate.
- Clinically significant abnormal laboratory results at screening, in the opinion of the Principal Investigator or delegate.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and/or total bilirubin levels greater than 1.5 × the upper limit of normal (ULN) at screening.
- Estimated glomerular filtration rate (eGFR) Less than or equal 90 milliliter/minute/1.73 meter square at screening, calculated using the CKD-EPI equation.
- Positive test results at screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen or antibody. Participants with a positive hepatitis B surface antibody (HBsAb) due to prior vaccination are permitted.
- Any current active infection, including localized infections, or a recent history (within 1 week prior to dosing) of infection, cough, or fever, or a history of recurrent or chronic infections.
- Any disease or history of surgery that, in the opinion of the Principal Investigator or delegate, could significantly affect the absorption, distribution, metabolism, or excretion of the investigational product.
- Positive pregnancy test or lactation in female participants.
- Positive urine drug screen, urine cotinine test, or alcohol breath test.
- History of clinically significant allergic reactions, including anaphylaxis, hypersensitivity, or angioedema, to any medication, or known allergy to GV-100, related compounds, or any formulation excipients.
- Clinically significant abnormalities in ECG findings or vital signs at screening, as determined by the Principal Investigator or delegate.
- Supine systolic blood pressure greater than or equal to 160 mmHg or diastolic blood pressure greater than or equal to 95 millimeters of mercury. (mmHg) at screening after at least 5 minutes of rest. If elevated, blood pressure will be repeated two additional times, and the average of three measurements will be used to assess eligibility.
- History of drug abuse within 6 months prior to first dosing, or substance abuse considered clinically significant by the Principal Investigator or delegate.
- History of alcohol abuse within 6 months prior to first dosing, defined as consumption exceeding 21 units per week for males or 14 units per week for females
(1 unit = 240 milliliter beer, 120 milliliter wine, or 30 milliliter distilled Alcohol).
- Use of depot injections or implants within 3 months prior to first dosing.
- Receipt of live or live-attenuated vaccines (bacterial or viral) within 12 weeks prior to screening, or planned receipt during the study period.
- Receipt of any vaccine, including COVID-19 vaccines, within 14 days prior to first dosing.
- Use of any drug known to induce or inhibit hepatic drug-metabolizing enzymes within 30 days or 5 half-lives (whichever is longer) prior to first dosing.
- Use of prescription medications within 14 days or 5 half-lives (whichever is longer) prior to first dosing.
- Use of over-the-counter medications or natural health products, including herbal remedies (e.g., St. John’s wort), traditional medicines, probiotics, dietary supplements, or sports supplements within 14 days or 5 half-lives (whichever is longer) prior to first dosing, except for occasional paracetamol up to 2 grams/day.
- Participation in another clinical research study involving an investigational or marketed drug or device within 30 days or 5 half-lives (whichever is longer) prior to first dosing; participation involving a biological product within 90 days prior to dosing; or concurrent participation in any investigational study without drug or device administration.
- Donation of plasma or platelets within 14 days prior to dosing, or donation or loss of equals 500 milliliter of whole blood within 60 days prior to dosing.
- Previous exposure to GV-100.
- Any other condition or circumstance that, in the opinion of the Principal Investigator or delegate, could interfere with study participation or compliance, which will be documented in the source records.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
An envelope for each participant containing his/her treatment assignment will be stored in a secure storage area at the clinical site.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321471 0
Commercial sector/Industry
Name [1] 321471 0
Gilva Therapeutics, INC.
Country [1] 321471 0
Taiwan, Province Of China
Primary sponsor type
Commercial sector/Industry
Name
Gilva Therapeutics, INC.
Address
Country
Taiwan, Province Of China
Secondary sponsor category [1] 324220 0
Commercial sector/Industry
Name [1] 324220 0
Novotech (Australia) Pty Limited
Address [1] 324220 0
Country [1] 324220 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320004 0
Bellberry Human Research Ethics Committee D
Ethics committee address [1] 320004 0
Ethics committee country [1] 320004 0
Australia
Date submitted for ethics approval [1] 320004 0
25/03/2026
Approval date [1] 320004 0
01/05/2026
Ethics approval number [1] 320004 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149114 0
Dr Jonathan Newchurch
Address 149114 0
CMAX Clinical Research, 21-24 North Terrace, Adelaide, SA 5000, Australia
Country 149114 0
Australia
Phone 149114 0
+61423223756
Fax 149114 0
Email 149114 0
Contact person for public queries
Name 149115 0
Jonathan Newchurch
Address 149115 0
CMAX Clinical Research, 21-24 North Terrace, Adelaide, SA 5000, Australia
Country 149115 0
Australia
Phone 149115 0
+61870887900
Fax 149115 0
Email 149115 0
Contact person for scientific queries
Name 149116 0
Jonathan Newchurch
Address 149116 0
CMAX Clinical Research, 21-24 North Terrace, Adelaide, SA 5000, Australia
Country 149116 0
Australia
Phone 149116 0
+61870887900
Fax 149116 0
Email 149116 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.